A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120n         in patients with relapsed advanced non-small-cell lung cancer

J. von Pawel

首页> 外文期刊>Annals of Oncology >A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120n in patients with relapsed advanced non-small-cell lung cancer

【24h】

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120n in patients with relapsed advanced non-small-cell lung cancer

机译：II期双盲研究，以研究两剂三联血管激酶抑制剂BIBF 1120n在复发性晚期非小细胞肺癌患者中的疗效和安全性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Background: To assess the efficacy, safety, tolerability and pharmacokinetics of BIBF 1120 in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC).

机译：背景：为了评估BIBF 1120在IIIB / IV期非小细胞肺癌（NSCLC）患者中的疗效，安全性，耐受性和药代动力学。

著录项

来源
《Annals of Oncology》 |2011年第6期|p.1374-1381|共8页
作者
J. von Pawel;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. [J] . Reck M, Kaiser R, Eschbach C, Annals of oncology: official journal of the European Society for Medical Oncology . 2011,第6期

机译：II期双盲研究旨在研究两剂三联血管激酶抑制剂BIBF 1120在复发性晚期非小细胞肺癌患者中的疗效和安全性。
2. Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients [J] . Peter M. Ellis, Rolf Kaiser, Yihua Zhao, Clinical cancer research: an official journal of the American Association for Cancer Research . 2010,第10期

机译：I期开放标签研究持续治疗经预处理的非小细胞肺癌患者使用BIBF 1120，三联血管激酶抑制剂和培美曲塞进行持续治疗
3. Prospective, multicenter, randomized, independent-group, open-label phase II study to investigate the efficacy and safety of three regimens with two doses of sagopilone as second-line therapy in patients with stage IIIB or IV non-small-cell lung cancer [J] . HeigenerD.F., vonPawelJ., EschbachC., Lung cancer: Journal of the International Association for the Study of Lung Cancer . 2013,第3期

机译：前瞻性，多中心，随机，独立组，开放标签的II期研究旨在研究两种剂量的sagopilone作为二线治疗在IIIB或IV期非小细胞肺癌患者中的疗效和安全性
4. The clinical efficacy of transfusion of cytokine-induced killer cells combined with chemotherapy and XiaoJi decoction in patients with stage IIIB/IV non-small cell lung cancer [C] . Liuning Li, Jiaying Liu, Xiaoshu Chai, IEEE International Conference on Bioinformatics and Biomedicine . 2014

机译：细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. A randomized multicenter phase II study comparing efficacy safety and tolerability of two dosing regimens of cisplatin and pemetrexed in patients with advanced or metastatic non-small-cell lung cancer [O] . Martin Metzenmacher, Hans-Georg Kopp, Frank Griesinger, 2021

机译：随机的多中心期II研究比较晚期或转移性非小细胞肺癌患者的二铂肽和Pemetrexed两种剂量方案的疗效安全性和耐受性进行比较
7. B1-03: Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC) [O] . Reck Martin, Kaiser Rolf, Eschbach Corinna, 2007

机译：B1-03：II期双盲研究旨在研究三联血管激酶抑制剂BIBF 1120在复发性晚期非小细胞肺癌（NSCLC）患者中的疗效和安全性

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120n in patients with relapsed advanced non-small-cell lung cancer

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅